Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptinyx Inc. stock logo
APTX
Aptinyx
$0.10
$0.08
$0.01
$0.72
N/A1.271.32 million shs231,126 shs
Harrow, Inc. stock logo
HROW
Harrow
$30.54
-1.1%
$27.77
$20.36
$59.23
$1.13B0.4494,484 shs449,935 shs
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
$0.24
0.0%
$0.28
$0.17
$0.48
$349.32M-1.092.02 million shs3.52 million shs
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
$2.00
$2.09
$1.85
$4.26
$135.66M1.58866,464 shs684,684 shs
Verastem, Inc. stock logo
VSTM
Verastem
$4.15
$6.57
$2.10
$9.10
$228.04M0.851.23 million shs2.37 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptinyx Inc. stock logo
APTX
Aptinyx
0.00%0.00%0.00%0.00%0.00%
Harrow, Inc. stock logo
HROW
Harrow
-1.10%-1.48%+8.14%+22.26%+46.19%
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
-0.04%-7.02%-12.12%+13.00%-43.79%
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
0.00%0.00%0.00%0.00%0.00%
Verastem, Inc. stock logo
VSTM
Verastem
0.00%-10.17%-44.30%-28.69%+39.26%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aptinyx Inc. stock logo
APTX
Aptinyx
N/AN/AN/AN/AN/AN/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
2.8718 of 5 stars
3.52.00.00.03.12.50.6
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
0.0148 of 5 stars
0.01.00.00.00.60.00.0
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Verastem, Inc. stock logo
VSTM
Verastem
2.8099 of 5 stars
3.53.00.00.01.92.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptinyx Inc. stock logo
APTX
Aptinyx
0.00
N/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
3.00
Buy$61.40101.05% Upside
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
0.00
N/AN/AN/A
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
0.00
N/AN/AN/A
Verastem, Inc. stock logo
VSTM
Verastem
3.00
Buy$13.38222.29% Upside

Current Analyst Ratings Breakdown

Latest SBBP, HROW, APTX, NWBO, and VSTM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Verastem, Inc. stock logo
VSTM
Verastem
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$16.00 ➝ $12.00
6/12/2025
Harrow, Inc. stock logo
HROW
Harrow
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$62.00
6/10/2025
Harrow, Inc. stock logo
HROW
Harrow
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
5/12/2025
Harrow, Inc. stock logo
HROW
Harrow
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$57.00 ➝ $60.00
5/9/2025
Verastem, Inc. stock logo
VSTM
Verastem
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$10.00 ➝ $14.00
4/10/2025
Verastem, Inc. stock logo
VSTM
Verastem
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$15.00
4/9/2025
Verastem, Inc. stock logo
VSTM
Verastem
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$9.00 ➝ $8.00
4/1/2025
Harrow, Inc. stock logo
HROW
Harrow
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$69.00 ➝ $65.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptinyx Inc. stock logo
APTX
Aptinyx
$1MN/AN/AN/A$0.57 per shareN/A
Harrow, Inc. stock logo
HROW
Harrow
$199.61M5.61$0.14 per share225.83$1.95 per share15.66
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
$1.38M253.02N/AN/A($0.07) per share-3.43
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
$30.73M4.41N/AN/A$0.98 per share2.04
Verastem, Inc. stock logo
VSTM
Verastem
$10K22,804.25N/AN/A($0.65) per share-6.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptinyx Inc. stock logo
APTX
Aptinyx
-$64.85M-$0.98N/AN/AN/AN/AN/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
-$17.48M-$0.56N/A76.35N/A-10.19%-25.01%-4.27%8/6/2025 (Estimated)
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
-$83.78M-$0.07N/AN/A-5,757.57%N/A-303.49%8/7/2025 (Estimated)
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
-$45.08M-$0.78N/AN/AN/A-115.67%-66.82%-36.21%N/A
Verastem, Inc. stock logo
VSTM
Verastem
-$130.64M-$3.20N/AN/AN/AN/A-2,003.62%-127.97%8/6/2025 (Estimated)

Latest SBBP, HROW, APTX, NWBO, and VSTM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
N/A-$0.01N/A-$0.01N/A$0.38 million
5/13/2025Q1 2025
Verastem, Inc. stock logo
VSTM
Verastem
-$0.72-$0.96-$0.24-$0.96$0.10 millionN/A
5/8/2025Q1 2025
Harrow, Inc. stock logo
HROW
Harrow
$0.02-$0.38-$0.40-$0.50$57.00 million$47.83 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aptinyx Inc. stock logo
APTX
Aptinyx
N/AN/AN/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
N/AN/AN/AN/AN/A
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
N/AN/AN/AN/AN/A
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
N/AN/AN/AN/AN/A
Verastem, Inc. stock logo
VSTM
Verastem
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptinyx Inc. stock logo
APTX
Aptinyx
N/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
2.01
0.91
0.85
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
N/A
0.06
0.06
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
0.38
3.00
2.95
Verastem, Inc. stock logo
VSTM
Verastem
2.77
3.50
3.50

Institutional Ownership

CompanyInstitutional Ownership
Aptinyx Inc. stock logo
APTX
Aptinyx
N/A
Harrow, Inc. stock logo
HROW
Harrow
72.76%
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
0.04%
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
52.03%
Verastem, Inc. stock logo
VSTM
Verastem
88.37%

Insider Ownership

CompanyInsider Ownership
Aptinyx Inc. stock logo
APTX
Aptinyx
10.97%
Harrow, Inc. stock logo
HROW
Harrow
13.67%
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
8.70%
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
5.10%
Verastem, Inc. stock logo
VSTM
Verastem
2.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptinyx Inc. stock logo
APTX
Aptinyx
12N/AN/ANot Optionable
Harrow, Inc. stock logo
HROW
Harrow
18236.69 million31.67 millionOptionable
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
201.46 billion1.33 billionNot Optionable
Strongbridge Biopharma plc stock logo
SBBP
Strongbridge Biopharma
7267.83 millionN/AOptionable
Verastem, Inc. stock logo
VSTM
Verastem
5054.95 million53.80 millionOptionable

Recent News About These Companies

Cantor Fitzgerald Reduces Earnings Estimates for Verastem

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aptinyx stock logo

Aptinyx NASDAQ:APTX

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

Harrow stock logo

Harrow NASDAQ:HROW

$30.54 -0.34 (-1.10%)
As of 06/30/2025 04:00 PM Eastern

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Northwest Biotherapeutics stock logo

Northwest Biotherapeutics OTCMKTS:NWBO

$0.24 0.00 (-0.04%)
As of 06/30/2025 03:59 PM Eastern

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Strongbridge Biopharma stock logo

Strongbridge Biopharma NASDAQ:SBBP

Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA.

Verastem stock logo

Verastem NASDAQ:VSTM

$4.15 0.00 (0.00%)
As of 06/30/2025 04:00 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.